Neil Sheppard

Director of Research Technologies & Innovation at the Center for Cellular Immunotherapies University of Pennsylvania

Monica Raimo is a Senior R&D manager at Glycostem Therapeutics, which she joined in 2018. In her role, she oversees process development for Natural Killer cell therapies, as well as the development of clinically compliant genetic modified strategies, and how to leverage “omics” studies for the generation of cell therapies.

Before joining Glycostem, she was a scientist at InteRNA Technologies, working in the development of non-coding RNA therapeutics. Previously, she obtained a PhD in Molecular Oncology from the University of Turin, Italy, understanding the molecular mechanisms driving metastatic progression of melanoma and breast cancer. Raimo has contributed to patent applications in the field of stem and NK cell ex vivo culture and genetic engineering, and has published scientific articles in the field of cancer biology and immunology, non-coding RNAs, NK cell therapies and bioinformatics.

Seminars

Wednesday 25th March 2026
Multiplex Engineering of NK Cells to Resist the Tumor Microenvironment for More Effective Activity & Therefore More Successful Therapies
3:00 pm
  • Disarming immune suppression by engineering NK cells to resist inhibitory signals
  • Overcoming NK cell-intrinsic checkpoints to boost NK metabolism and functional activity
  • Combining multiplex base editing and CAR and cytokine engineering to enhance activity to antigen positive and negative tumors
Neil Sheppard